With your good chance of getting dementia this test should be prescribed by your doctor to establish a baseline for you. And then if found implement THOSE EXACT DEMENTIA PREVENTION PROTOCOLS your doctor should have competently already set up.
Your risk of dementia, has your doctor told you of this?
1. A documented 33% dementia chance post-stroke from an Australian study? May 2012.
2. Then this study came out and seems to have a range from 17-66%. December 2013.`
3. A 20% chance in this research. July 2013.
4. Dementia Risk Doubled in Patients Following Stroke September 2018
The latest here:
Lower Levels of Abeta42 in Blood at Midlife Linked to Increased Risk of Dementia, Mild Cognitive Impairment
A study published in Neurology
found that people who went on to develop dementia or mild cognitive
impairment (MCI) had a lower level of amyloid beta 42 (Abeta42) in their
blood at midlife than those who did not.
“Right now we look at levels of the protein amyloid beta in the central nervous system as a biomarker of Alzheimer’s disease, but the only way to do that is through brain scans or looking at the cerebrospinal fluid via a lumbar puncture,” said Kevin J. Sullivan, PhD, University of Mississippi Medical Center, Jackson, Mississippi. “These new results suggest that there is utility in using simple blood draws that would be less expensive and much less invasive for people.”
The study involved 2,284 people with an average age of 59 years who did not have problems with memory or thinking skills at the start of the study. The people’s blood level of amyloid beta was tested with samples from the beginning of the study, which the researchers called the midlife test, and then again when they were about 77 years old, or the late life test.
The people were given thinking and memory tests over the 25 years of the study to determine whether they developed dementia or MCI. A total of 502 people developed dementia and 832 developed mild cognitive impairment.
The researchers looked at levels of both Abeta42 and amyloid beta 40 (Abeta40), and the ratio between the two. They found that lower levels of Abeta42 at midlife, but not late life, was associated with the higher risk of dementia and marginally higher risk of MCI. Every 10 pg/mL increase in the blood of Abeta42 was associated with a 13% lower risk of MCI or dementia.
However, higher levels of Abeta40 were associated with higher risk of dementia and MCI at both midlife and late life. Every 67 pg/mL increase in the blood of Abeta40 was associated with a 15% increased risk of MCI or dementia.
A lower ratio of Abeta42 to Abeta40 was associated with a higher risk of dementia and MCI, but only up to the median level. After that, an increase in the ratio was not related to risk of dementia.
“A doubling of this ratio under this threshold at midlife was associated with a 37% lower risk of MCI or dementia, which is comparable to about 5 years of younger age, and a doubling of this ratio under this threshold at late life was comparable to about 3 years younger age,” said Dr. Sullivan. “Amyloid in the blood may be useful as a biomarker for risk of future cognitive impairment.”
The results were the same after researchers adjusted for other factors that could affect cognitive impairment, such as age, education and cardiovascular risk factors.
A limitation of the study was that an older testing method was used to estimate blood levels of amyloid beta that is not as precise as newer methods of testing. The study does not prove the blood test can be used to predict who will develop dementia later in life.
Reference: https://n.neurology.org/content/96/5/e662
SOURCE: American Academy of Neurology
“Right now we look at levels of the protein amyloid beta in the central nervous system as a biomarker of Alzheimer’s disease, but the only way to do that is through brain scans or looking at the cerebrospinal fluid via a lumbar puncture,” said Kevin J. Sullivan, PhD, University of Mississippi Medical Center, Jackson, Mississippi. “These new results suggest that there is utility in using simple blood draws that would be less expensive and much less invasive for people.”
The study involved 2,284 people with an average age of 59 years who did not have problems with memory or thinking skills at the start of the study. The people’s blood level of amyloid beta was tested with samples from the beginning of the study, which the researchers called the midlife test, and then again when they were about 77 years old, or the late life test.
The people were given thinking and memory tests over the 25 years of the study to determine whether they developed dementia or MCI. A total of 502 people developed dementia and 832 developed mild cognitive impairment.
The researchers looked at levels of both Abeta42 and amyloid beta 40 (Abeta40), and the ratio between the two. They found that lower levels of Abeta42 at midlife, but not late life, was associated with the higher risk of dementia and marginally higher risk of MCI. Every 10 pg/mL increase in the blood of Abeta42 was associated with a 13% lower risk of MCI or dementia.
However, higher levels of Abeta40 were associated with higher risk of dementia and MCI at both midlife and late life. Every 67 pg/mL increase in the blood of Abeta40 was associated with a 15% increased risk of MCI or dementia.
A lower ratio of Abeta42 to Abeta40 was associated with a higher risk of dementia and MCI, but only up to the median level. After that, an increase in the ratio was not related to risk of dementia.
“A doubling of this ratio under this threshold at midlife was associated with a 37% lower risk of MCI or dementia, which is comparable to about 5 years of younger age, and a doubling of this ratio under this threshold at late life was comparable to about 3 years younger age,” said Dr. Sullivan. “Amyloid in the blood may be useful as a biomarker for risk of future cognitive impairment.”
The results were the same after researchers adjusted for other factors that could affect cognitive impairment, such as age, education and cardiovascular risk factors.
A limitation of the study was that an older testing method was used to estimate blood levels of amyloid beta that is not as precise as newer methods of testing. The study does not prove the blood test can be used to predict who will develop dementia later in life.
Reference: https://n.neurology.org/content/96/5/e662
SOURCE: American Academy of Neurology
